BACKGROUND: Huntington's disease is marked by progressive neuroanatomical changes, assumed
Introduction
Huntington's disease (HD) causes progressive neurodegeneration, leading to debilitating motor, cognitive and psychiatric symptoms. Despite identification of the gene responsible for HD [1] and subsequent years of concerted clinical and research efforts, the search for disease-modifying treatments is still in its infancy.
Studying HD in vivo using magnetic resonance imaging (MRI) is a powerful approach for improving our understanding of the disease's progressive nature. Used to elucidate aspects of the neural pathogenesis of HD in the striatum, studies using volumetric approaches have also shown that HD pathology extends to macrostructural abnormalities within cortical and white matter regions [2] [3] [4] [5] [6] .
By employing diffusion tensor imaging (DTI), we can similarly investigate microstructural changes in white matter with several studies already having identified abnormalities in manifest HD genecarriers [7] [8] [9] [10] [11] , pre-manifest HD (preHD) gene carriers [12] [13] [14] [15] [16] [17] and across multiple disease stages [5, [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] .
Cross-sectional DTI studies which have included both preHD and early-HD gene-carriers have attempted to characterise disease progression, but this is better achieved by conducting longitudinal analyses which can map individual patterns of change. There is strong evidence of progressive macrostructural white matter degeneration [31] [32] [33] [34] [35] [36] [37] [38] [39] and current evidence suggests that longitudinal change in caudate nucleus volume is a particularly promising candidate neuroimaging biomarker for future clinical trials [36] . If the microstructural properties captured by DTI are more sensitive to the cellular processes underlying neurodegeneration [40] , DTI may potentially be a better index of HD progression than macrostructural volumetric methods. Thus, further longitudinal DTI analysis of white matter in HD is warranted. However, only a limited number of studies have examined DTI in HD longitudinally (see Rees et al., for review [41] ) and these have generally either been restricted to striatal grey matter regions [42, 43] , or limited in sample size and scope. For example, white matter change was investigated in a small combined group (N = 7) of early HD and preHD gene carriers using whole-brain tract-based spatial statistics (TBSS) [44, 45] . This preliminary research identified longitudinal decreases in fractional anisotropy (FA) and axial diffusivity (AD) after one year in the HD patients when compared to a matched control group. Conversely, Sritharan and colleagues [46] were unable to detect similar changes over the same interval, using a region-of-interest (ROI) approach in a larger sample of 18 HD patients and 17 controls. However, this analysis only examined mean diffusivity (MD) of the corpus callosum. A recent study has investigated longitudinal change over 18 months using data from two timepoints in a larger group of preHD and early HD genecarriers [29] . Again, using TBSS, they have shown that when compared to both preHD and control groups, early HD gene-carriers have reduced FA in the genu, body and splenium of the corpus callosum and mid cingulum and that callosal FA levels are predicted by the Unified Huntington's Disease Rating Scale Total Motor Score (UHDRS-TMS) [47] . Furthermore, there was evidence of increased radial diffusivity (RD) in the corpus callosum, cingulum, internal capsule and striatal projections when compared to the premanifest, but not the control group.
Another recent study applying histogram analysis to DTI data over 24 months using data from two timepoints, assessed microstructural properties of whole-brain gray matter, white matter and the striatum in different stages of HD [30] . In that study evidence was found for alterations in crosssectional diffusion profiles between early manifest HD and preHD subjects compared to healthy controls, without evidence for longitudinal differences in the degree of diffusivity change between the groups. Investigating the structural connectome using the same dataset by applying graph theoretical analysis, Odish and colleagues revealed longitudinal differences between early manifest HD, preHD subjects and controls in various network measures [48] . These results further emphasise the importance of exploring different analytical approached to study the biomarker potential of diffusion MRI.
The aim of the current study was to investigate progressive alterations in white matter microstructure during the early stages of symptomatic HD using multi-site DTI data combined with an ROI approach. To more clearly characterise longitudinal change, we used three timepoints over a 5 15 month interval to track the subtle, non-linear changes in progression across this period. We focussed on FA as a measure of the direction of diffusivity, in addition to both AD and RD which respectively index water movement parallel and perpendicular to the main fibre. We investigated white matter changes with respect to genetic factors (i.e. CAG repeat length) and disease burden, as these markers of HD show associations with cross-sectional white matter abnormalities [8, 23, 24] and in using the ROI approach, this analysis was designed to highlight specific brain regions for future evaluation as DTI-derived biomarkers for potential therapeutic studies.
Materials and Methods

Participants
61 HD patients and 40 control participants were recruited as part of the PADDINGTON study [11] across four study sites (Leiden, Netherlands; London, UK; Paris, France; Ulm, Germany). Participants attended three separate study visits, with an initial baseline and subsequent 6-month and 15-month follow-ups. Due to a combination of participant dropout, missing data and quality control failure, 17 participants (13 HD patients, 4 controls) did not have complete diffusion MRI datasets for all three visits (two missing 6-month assessment; 15 missing 15-month); hence 84 participants (48 HD patients and 36 controls -see Table 1 ) were included in the final analysis. These exclusions were necessary as the longitudinal image registration scheme outlined below cannot account for missing image data. Excluded HD patients had marginally higher disease burden and Total Motor Score (TMS) and lower Total Functional Capacity (TFC) at baseline but overall the demographic differences were minimal (see Supplementary Table 1 ).
In addition to MRI data, behavioural, cognitive and clinical assessments were performed at each visit. All patients had received a diagnosis of manifest HD, were at disease stage I [49] and had a baseline UHDRS TFC score between 11-13. One patient had a TFC score of 9 and was classified as disease stage II (this score remained stable across all study visits). CAG repeat length was assessed to confirm diagnosis and all patients had between 39-54 repeats. Control participants were spouses, 6 partners or gene-negative siblings of the HD patients. Inclusion criteria were: 18-65 years of age, no diagnosis of psychiatric or other neurological disorders, not currently taking part in other pharmacological research and no contraindication to MRI scanning. The respective local ethical committees for each study site approved the study and written informed consent was obtained from each participant.
Data acquisition
3T MRI Diffusion-weighted T1 structural and DTI images were acquired at all sites. For further details on acquisition parameters and pooling of multi-site site data see our previous work on this sample [11, 50] . Visual quality control was performed to check for acquisition protocol compliance, artefacts and head positioning. Rescans were requested for four participants and scans were excluded due to failure to meet the required quality criteria, leaving 84 participants for the analysis. All image processing and analysis was performed blinded to participant diagnosis. All site effects were modelled within the analysis.
Data pre-processing
Diffusion-weighted images were initially registered to the corresponding b0 reference image to correct for motion and eddy current distortions, with updates applied to the gradient scheme accordingly. Subsequently, a non-linear least-squares method was used to fit the tensor at each voxel, using Camino [51] . Tensor-based registration was then performed using DTI-TK (http://dtitk.sourceforge.net) [52] . This offers improvements over conventional scalar-based registration as it incorporates information from local fibre orientations and has been shown to improve the sensitivity of DTI metrics to microstructural group differences [53, 54] and the performance of study-specific atlas generation [55] . We employed a well-established specific longitudinal registration procedure, which registers average within-subject templates to a study-specific group template; this avoids biases caused by asymmetric image registration or imbalanced application of interpolation schemes [56] (see Figure 1 ). In short, for every participant, tensor images for each visit were co-registered together to form a 'bootstrap' template, then each image was non-linearly registered to the template using an iterative approach. The resulting affine and non-linear registrations were then combined so that the input images could be mapped to subject-template space in one interpolation step [57] . A group template was then created using this same iterative affine and non-linear procedure; with participant average images as input. Again, transformations were combined to take within-participant template images to group template space with one interpolation. This resulted in all participants' tensor images being spatially normalised to a study-specific group template, from which individual subject maps for FA, AD and RD could be generated for further processing and statistical analysis.
Atlas-based ROI analysis
To define our ROIs, we used the 2mm 3 ICBM-DTI-81 atlas [58] employed within FSL software. Based on our previous work [59] , the number of regions was reduced from 48 to 24 to include only those with high test-retest reliability for FA, AD and RD (i.e. intraclass correlation coefficient > 0.8) (Tables   2 and 3 ). It should be noted that the current sample includes the subsample reported in [59] .
However, the analysis in that study used sequentially acquired data from a single visit, not multiple timepoints, and therefore presents no confound when using that data to inform the selection of
ROIs for the present study. The DTI-81 atlas was registered to the group FA template using the NiftyToolkit (http://sourceforge.net/projects/niftyreg) components Aladin, for affine registration [60] and F3D, for non-linear refinement [61] . The computed transformation was then used to warp the label files to match the group FA template. The group FA template was thresholded at FA > 0.2 and belowthreshold voxels removed from DTI-81 label images in group-template space. The mean value of each metric (FA, AD and RD) was then calculated across each ROI for each participant at each visit.
Statistical analysis
All analysis was conducted in STATA version 13. The repeated measures of each ROI/metric combination were separately analysed using generalised least squares regression models, with outcome variance (and correlations between pairs of measures) allowed to differ both by disease group and by visit. The models included a group factor (HD patient or Control), time from baseline (in days) and a quadratic term that modelled non-linear change over the three visits. Also, baseline covariates of age, sex and study site were included. Interaction terms between time (both linear and quadratic) and all other variables were included. The primary measures of interest were group differences at baseline and in change over 15 months. Due to the large number of ROIs and ensuing increased risk of false positives, a correction for multiple testing was carried out using a procedure to control the False Discovery Rate (FDR) [62] at 5%. It was considered appropriate to do this for each metric separately, thus corrections were based on analysing 24 ROIs. Due to a priori concern of between-site differences, two interaction terms were tested using the same multiple comparison procedure as above: baseline interaction between group and study site, three-way site by group by time (both linear and quadratic) interaction. If the three-way interaction was significant, then both the baseline group differences and the between-group difference in 15-month change were reported by site. If only the baseline interaction between site and group was significant, this was retained in the model and a single between-group difference in 15-month change reported (nonsignificant three-way interactions were removed for clarity). If neither interaction was statistically significant they were both removed from the model. FDR correction for the primary measures of interest was conducted after removal of any measures that needed to be reported as site-specific.
Clinical associations
Longitudinal imaging measures were tested for associations with baseline CAG and disease burden score DBS) in the HD participant group only. This was restricted to those measures identified as having shown significant between-group differences in 15-month change. For simplicity, a linear regression was used to model 15-month change with an adjustment for the baseline diffusion value.
Additional adjustments were also made for age, sex and study site. Again, interaction between group and site was allowed for, and if significant, site-specific associations were presented. If not, the interaction was removed from the model. As above, p-values were adjusted using FDR correction at 5%, this time based on the number of measures carried through to the secondary analysis.
Results
Baseline comparison of early HD patients and controls
To provide context for understanding longitudinal changes, we investigated cross-sectional differences between early HD patients and controls at baseline. All 24 regions showed statistically significant group differences (corrected for multiple comparisons) for at least one metric, with the HD group demonstrating either decreases in FA or increases in AD or RD when compared with controls ( Table 2 ). Regions where all three DTI metrics showed significant differences were the three subdivisions of the corpus callosum (genu, body and splenium), the left external capsule and left bilateral sagittal stratum. There were no regions where increased FA was evident in the HD group, nor where decreased AD or RD was found.
Comparison of longitudinal changes in early HD patients and controls
DTI metrics showed significant differences in rates of change between early HD patients and controls in nine regions (see Figure 2 and Table 3 ). The genu and body of the corpus callosum showed reduced FA and increased RD, with increased AD in the genu only. There was increased RD and AD in the left anterior corona radiata; and increases in AD were also evident in both the right superior corona radiate and anterior limb of internal capsule. All differences were significant following multiple correction. Four metrics showed evidence of interaction between group differences in 15-month change and site (see Supplementary Table 2) .
If between-group differences were driven by disease, we would expect to see a relatively flat trajectory of DTI measures over time for the control group, coupled with a deterioration in HD subjects to reflect disease progression. As an informal check, we plotted the model-estimated trajectories of diffusivity measures throughout the study period in controls and HD groups influencing the detected group differences in rates of change over time.
Clinical associations with longitudinal neuroimaging measures
The nine measures that reached statistical significance for longitudinal change (Table 3) were examined for associations between 15-month change and baseline CAG and disease burden in the HD subjects. Estimates and 95% confidence intervals are displayed in [29] . Both the current study and that of
Poudel have shown that in early HD there are FA increases and RD decreases in the corpus callosum when compared with controls. Although this previous study used only two timepoints, incorporating a longer period of change, and a whole-brain rather than an a priori hypothesis driven method, findings are still highly consistent regarding the corpus callosum. These three studies highlight a consistent disturbance within the corpus callosum above all other white matter tracts. This is compatible with the aforementioned extant evidence at the cross-sectional level which robustly demonstrates white matter abnormalities within the corpus callosum. Despite concordance concerning measures of RD and FA, there is far greater inconsistency in terms of AD measures. We saw increased AD not only in the corpus callosum, but also the anterior and superior corona radiate and the anterior internal capsule. Weaver, however, reported decreased AD in a small set of voxels [45] , these differences likely due to low statistical power and variability in terms of disease progression; while Poudel et al. did not show any significant differences in AD at all [29] . Crosssectional studies of early HD patients have previously shown increases in AD compared with controls [7, 11, 18, 27, 30] and there is evidence that the negative correlation between AD and RD acts as an independent predictor of HD disease progression (see unpublished data -Mike O). However, given the limited number of studies examining longitudinal change in white matter, further replication of our findings would be required to confirm the increases in AD in early HD gene-carriers. It is important to note that some longitudinal differences may potentially be driven by a regression to the mean in controls, rather than being explicitly disease-related. Nevertheless, some regions do appear to show a consistent trajectory of change in early HD patients, while those of the controls remaining static (e.g. genu FA, right anterior limb of internal capsule AD, right superior corona radiata AD, left anterior corona radiata RD).
Inferring specific biological processes underlying alterations in DTI metrics can be contentious [64] .
Animal studies combining DTI and histology to model white matter damage [65, 66] and HD specifically [67] have indicated that differing pathological processes may underlie AD and RD measurements. Under this assumption, RD increases reflect demyelination [68] , while changes in AD are more complex and time-dependent. Decreases in AD are thought to occur in response to acute axonal damage and inflammation [69] ; conversely AD increases reflect expanded extra-cellular spaces resulting from Wallerian degeneration and other more gross atrophic processes [70, 71] .
However, we would caution against the over-interpretation of instances where, for example, AD was significant and RD was not. Cellular modifications caused by HD pathology undoubtedly affect white matter, but the mechanisms underlying this are unclear. Elements of intrinsic axonal degeneration, altered fibre coherence or configuration due to inflammation, decreased axonal density or demyelination all occur during the progression of HD and current DTI methods lack such aetiological specificity. More recent developments in diffusion MRI [72] [73] [74] [75] [76] , may be more aetiologicallyinformative regarding microstructural white matter changes occurring during HD progression. Combining data from multiple scanners can present limitations, however our previous work has demonstrated that the cross-site pooling of data does not introduce bias in DTI analyses [50] .
Furthermore, longitudinal within-participant change measures were not confounded by scanner differences. Our study did not model any potentially confounding effects of medication on white matter metrics. However, given the considerable heterogeneity in medication usage among the participants, it would not have been possible to test medication effect systematically.
In conclusion, patients in the early stages of clinically-manifest HD show robust abnormalities in white matter structure throughout the brain, most robustly in the corpus callosum. Moreover, some of those regions appear to be undergoing microstructural degeneration as the disease progresses during the early diagnosed stages, with some evidence for a relationship between disease burden and structure of the corpus callosum. Despite these findings, our results demonstrate the difficulties in mapping effects of clinical variables onto a dynamically and heterogeneous pattern of brain changes that take place during early HD. Novel diffusion imaging methods which provide more information regarding the biological underpinnings of changes in white matter microstructure are required to further understand the heterogeneity of such alterations within HD. Furthermore, the use of multivariate modelling, which incorporates both imaging and clinical data, will also help to understand how white matter changes are related to clinical symptoms. Overview of the unbiased longitudinal registration methods. (A) Within-subject registration performed on tensor images using an initial affine and subsequent non-linear step in DTI-TK to warp images from each visit to a withinsubject 'mid-space'. A within-subject average template was then generated. (B) These within-subject average images were registered together, again using DTI-TK, to define a longitudinal between-subject space. The initial input images were then warped to this between-subject space and averaged to form a longitudinal group template, specific to the study. (C) Using NiftyReg to calculate affine and non-linear registrations, the FA image from the ICBM-DTI-81 atlas was then warped to match the group template. The parameters of this registration were then applied to ICBM-DTI-81 labels. (D) Finally, subject and visit specific metrics for each ROI were calculated. Longitudinal trajectories of DTI metrics for early HD patients and controls for all significant metric-ROI combinations.
Tables
The fitted values depicted were calculated for hypothetical participants age 50, with a 50/50 male-female split and a 25% contribution from each site. Points are plotted at each assessment (baseline, 6 months, 15 months), with the dashed line representing early HD patients and the whole line representing controls. 
Diffusion Tensor Imaging: Motion
Motion can be a major confounding factor in diffusion MRI. We, therefore, adopted a number of measures to combat the effects of motion on the quality of our DTI data. Firstly, during the scanning session, all participants had padding surrounding the head to reduce motion and were asked to keep very still while the DTI sequence was performed. We are aware, that participants with HD are more prone to movement within the scanner given the nature of their condition and therefore, may induce more motion artefacts than a healthy control group. It is important to note that, however, that, all but one of the patients were Stage 1-HD, having only recently received clinical motor diagnosis of HD and so their movement within the scanner would be potentially lower than other HD patients in more advanced stages of the disease. Nevertheless, it was likely that HD patient data would show more effect of motion and so we implemented a strict visual quality control procedure. For each participant, we inspected every slice of all gradient and non-gradient volumes for each timepoint. This is a very effective way of identifying motion-related artefacts, while also ensuring even sampling (which is not the case with automated quality control software). Following tensorfit and at every subsequent stage of pre-processing, the data were visually inspected for possible effects of motion.
Most importantly, prior to any processing, we corrected the data for any motion-induced currents using eddy-current correction in FSL; the b-vectors (gradient directions) were then updated accordingly and this updated motion-related information used in subsequent processing steps. A recent study investigated the effects of movement on the quality of DTI data in the HD population, using an outlier detection algorithm to compare the index DWI direction against a weighted average computed from all other directions of the same subject [22] . This study showed that no significant differences were observed when independently comparing groups of patients, both with and without removal of DWI volumes that contained artefacts and that further still, hypothesized white matter differences based on the existing literature were still detectable.
Correction for white matter atrophy
We chose not to control for white matter atrophy, because we believe that the disease processes underlying macroscopic white matter volume changes are strongly related to those which result in white matter microstructural changes. Consequently, co-varying for white matter atrophy would confound the disease effect under investigation. 
